Abstract

Hypertension, a prevalent cardiovascular condition, poses significant health risks worldwide. While antihypertensive medications effectively manage blood pressure, individual responses vary widely, necessitating personalized treatment strategies. Pharmacogenomics, the study of genetic influences on drug response, offers a promising avenue for precision management of hypertension. This abstract explores the role of pharmacogenomics in tailoring antihypertensive therapy to individual genetic profiles, optimizing treatment efficacy and minimizing adverse effects. Genetic variants in drug metabolism pathways, renin-angiotensin-aldosterone system genes, and blood pressure regulatory pathways influence responses to antihypertensive drugs. By integrating pharmacogenomic information into clinical practice, clinicians can enhance blood pressure control and reduce cardiovascular risk in hypertensive patients. Despite challenges such as limited access to testing and interpretation of genetic data, pharmacogenomics represents a transformative approach to personalized medicine in hypertension management, paving the way for improved patient outcomes and enhanced cardiovascular care.